Novel integrative genomics approach for associating GWAS information with intrinsic subtypes of breast cancer

Cancer Informatics

Volumn 12, Issue , 2013, Pages 125-142

  Hicks, Chindo ^a,b   Koganti, Tejaswi ^a   Brown, Alexandra S ^b   Monico, Jesus ^b   Backus, Kandis ^a   Miele, Lucio ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

GWAS subtypes breast cancer

Indexed keywords

ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER RISK; CONTROLLED STUDY; GENE IDENTIFICATION; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOMICS; HUMAN GENOME; MEDICAL INFORMATION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84877972217     PISSN: None     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/CIN.S11452     Document Type: Article

References (52)

1. Hicks C, Asfour R, Pannuti A, Miele L. An integrative genomics approach to biomarker discovery in breast cancer. Cancer Inform. 2011;10:185-204.
2. Zhang B, Beeghly-Fadiel A, Long J, Wei Z. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet. 2011;12:477-88.
3. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
4. Sorlie T. Molecular portraits of Breast cancer: tumour subtypes as distinct disease entities. Eur J.Cancer. 2004;40:2667-75.
5. Mavaddat N, Dunning AM, Ponder BA, Easton DF, Pharoah PD. Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. Cancer Epidem Biomarker Prev. 2009;18(1):255-9.
6. Broeks A, Schmidt MK, Sherman ME, et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: Findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2011;20:1-15.
7. Yang XR, Chang-Claude J, Goode EL, et al. 2011. Associations of breast cancer risk factors with tumor subtypes: A pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103:250-63.
8. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature. 2009;461:218-23.
9. Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: Interim guidelines. Int J Epidemiol. 2008;37:120-32.
10. Khoury MJ, Bertram I, Boffetta P, et al. Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation in human diseases. Am J Epidemiol. 2009;170:269-79.
11. Sagoo GS, Little J, Higgins JP. Systematic reviews of genetic association studies. Human Genome Epidemiology Network. PLoS Med. 2009;6:e28.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-9.
13. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
14. Perou CM. Molecular stratification of triple-negative breast cancer. Oncologist. 2011;16(Suppl 1):61-70.
15. Lehmann BD, Bauer JA, Chen X, et al. Identification of triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2012;121:2750-67.
16. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucl Acids Res. 2002;30(1):207-10.
17. Sabatier R, Finetti P, Cervera N, et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat. 2011;126:407-20.
18. Chen D, Nasir A, Culhane A, et al. Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat. 2010;119(2):335-46.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Stat Soc Series B. 1995;57(1):289-300.
20. RadMacher MD, McShane LM, Simon R. A paradigm for class prediction using gene expression profiles. J Comput Biol. 2002;9(3):505-11.
21. Morrissey ER, Diaz-Uriarte R. Pomello II: Finding differentially expressed genes. Nucleic Acids Res. 2009;37:W581-6.
22. Reich M, Liefield T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet. 2006;38(5):500-1.
23. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Nat Acad Sci U S A. 1998;95:14863-8.
24. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontolgy Consortium. Nat Genet. 2000;25(1):25-9.
25. Ingenuity Pathways Analysis (IPA) system. Ingenuity Incorporated, California.
26. Stevens KN, Vachon CM, Lee AM, et al. Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res. 2011;71(19):6240-9.
27. Stevens KN, Fredericksen Z, Vachon CM, et al. 19p13.1 Is a triple-negative-specific breast cancer susceptibility locus. Cancer Res. 2012;72(7): 1795-803.
28. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor (ER) status. Cancer Res. 2008;14(24):8000-9.
29. Holmans P, Green EK, Pahwa JS, et al. Gene ontology analysis of GWA study data sets provides insights into biology of bipolar disorder. Am J Hum Genet. 2009;85:13-24.
30. Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci of human diseases and traits. Proc Nat Acad Sci U S A. 2009;106:9362-7.
31. Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166-76.
32. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486:395-9.
33. Allocco DJ, Kohane IS, Butte AJ. Quantifying the relationship between co-expression, co-regulation and gene function. BMC Bioinformatics. 2004; 5:18.
34. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet. 2008;9:356-69.
35. Tommiska J, Bartkova J, Heinonen M, et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene. 2008;27(17):2501-6.
36. Angèle S, Hall J. The ATM gene and breast cancer: is it really a risk factor? Mutat Res. 2000;462(2-3):167-78.
37. Hall J. The Ataxia-telangiectasia mutated gene and breast cancer: gene expression profiles and sequence variants. Cancer Lett. 2005;227(2): 105-14.
38. Durocher F, Labrie Y, Soucy P, et al. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer. 2006:29(6):230.
39. Hicks C, Kumar R, Pannuti A, et al. An integrative genomics approach for associating GWAS information with triple-negative breast cancer. Cancer Inform. 2013;12:1-20.
40. Neboori HJ, Haffty BG, Wu H, et al. Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(5):e677-83.
41. Bouwman P, Aly A, Escandell JM, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010;17(6):688-95.
42. Bartkova J, Tommiska J, Oplustilova L, et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol. 2008; 2(4):296-316.
43. Powell SN, Kachnic LA. Therapeutic exploitation of tumor cell defects in homologous recombination. Anticancer Agents Med Chem. 2008;8(4): 448-60.
44. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411(6841):1017-21.
45. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501-12.
46. Stratton MS, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet. 2008;40(1):17-22.
47. Menashe I, Maeder D, Garcia-Closas M, et al. Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. Cancer Res. 2010;70(11):4453-9.
48. Haiman CA, Hsu C, de Bakker PI, et al. Comprehensive association testing of common genetic variation in DNA repair pathways genes in relationship with breast cancer risk in multiple populations. Hum Mol Genet. 2008; 17(6):825-34.
49. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW. Allelic variation in human gene expression. Science. 2002;297:1143.
50. Buckland PR. Allele-specific gene expression differences in humans. Hum Mol Genet. 2004;13(2):R255-60.
51. Paracios R, Gazave E, Goni J, et al. Allelle-specific gene expression is widespread across the genome and biological processes. PLoS One. 2009;4(1): e4150.
52. Meyer KB, Maja A-T, O'Reilly M, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol. 2008;6(5): e108.